- 专利标题: BENDAMUSTINE LIQUID COMPOSITIONS FOR USE IN METHOD OF TREATING BENDAMUSTINE-RESPONSIVE CONDITIONS IN PATIENTS REQUIRING REDUCED VOLUMES FOR ADMINISTRATION
-
申请号: EP19151152.6申请日: 2013-03-15
-
公开(公告)号: EP3533447A1公开(公告)日: 2019-09-04
- 发明人: SUNDARAM, Srikanth , TARRIFF, Scott, L.
- 申请人: Eagle Pharmaceuticals, Inc.
- 申请人地址: 50 Tice Boulevard Suite 315 Woodcliff Lake, NJ 07677 US
- 专利权人: Eagle Pharmaceuticals, Inc.
- 当前专利权人: Eagle Pharmaceuticals, Inc.
- 当前专利权人地址: 50 Tice Boulevard Suite 315 Woodcliff Lake, NJ 07677 US
- 代理机构: Oates, Edward Christopher
- 优先权: US201261613173P 20120320; US201261669889P 20120710; US201261678715P 20120802
- 主分类号: A61K31/4184
- IPC分类号: A61K31/4184 ; A61K47/10 ; A61K9/00 ; A61K47/02 ; A61K47/20
摘要:
Methods of treating bendamustine responsive conditions in patients having fluid and/or sodium intake restrictions are disclosed. The methods include identifying patients having such restrictions and in need of bendamustine, and then administering thereto a bendamustine-containing composition in a volume of about 120 ml or less intravenously over a period of about 15 minutes or less. The smaller volumes and reduced sodium load as compared to currently known methods of treatment minimize cardiac and/or renal stress in patients having diseases such as congestive heart failure or renal disease.
公开/授权文献
信息查询
IPC分类: